Anixa Biosciences (ANIX) 10-Q12 Mar 242024 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Jan. 31, 2024	Mar. 12, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2024
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--10-31
Entity File Number	001-37492
Entity Registrant Name	ANIXA BIOSCIENCES, INC.
Entity Central Index Key	0000715446
Entity Tax Identification Number	11-2622630
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3150 Almaden Expressway
Entity Address, Address Line Two	Suite 250
Entity Address, City or Town	San Jose
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95118
City Area Code	(408)
Local Phone Number	708-9808
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	ANIX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		31,899,800

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 31, 2023
Current assets:
Cash and cash equivalents	$ 998	$ 915
Short-term investments	22,800	22,929
Receivables	391	270
Prepaid expenses and other current assets	1,030	1,242
Total current assets	25,219	25,356
Operating lease right-of-use asset	153	166
Total assets	25,372	25,522
Current liabilities:
Accounts payable	364	206
Accrued expenses	1,242	1,770
Operating lease liability	54	52
Total current liabilities	1,660	2,028
Operating lease liability, non-current	108	123
Total liabilities	1,768	2,151
Commitments and contingencies (Note 10)
Equity:
Preferred stock, value
Common stock, par value $.01 per share; 100,000,000 shares authorized; 31,754,375 and 31,145,219 shares issued and outstanding as of January 31, 2024 and October 31, 2023, respectively	318	311
Additional paid-in capital	255,738	252,222
Accumulated deficit	(231,451)	(228,196)
Total shareholders’ equity	24,605	24,337
Noncontrolling interest (Note 2)	(1,001)	(966)
Total equity	23,604	23,371
Total liabilities and equity	25,372	25,522
Series A Convertible Preferred Stock [Member]
Equity:
Preferred stock, value

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jan. 31, 2024	Oct. 31, 2023
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	19,860	19,860
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	31,754,375	31,145,219
Common stock, shares outstanding	31,754,375	31,145,219
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 100	$ 100
Preferred stock, shares authorized	140	140
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue
Operating costs and expenses:
Research and development expenses (including non-cash share-based compensation expenses of $489 and $505, respectively)	1,349	1,068
General and administrative expenses (including non-cash share-based compensation expenses of $771 and $558, respectively)	2,260	1,488
Total operating costs and expenses	3,609	2,556
Loss from operations	(3,609)	(2,556)
Interest income	319	202
Net loss	(3,290)	(2,354)
Less: Net loss attributable to noncontrolling interest	(35)	(32)
Net loss attributable to common shareholders	$ (3,255)	$ (2,322)
Net loss per common share attributable to common shareholders:
Basic	$ 0.10	$ 0.08
Diluted	$ 0.10	$ 0.08
Weighted average common shares outstanding:
Basic	31,446	30,921
Diluted	31,446	30,921

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Research and Development Expense [Member]
Non-cash share-based compensation expenses	$ 489	$ 505
General and Administrative Expense [Member]
Non-cash share-based compensation expenses	$ 771	$ 558

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Parent [Member]	Noncontrolling Interest [Member]
Balance at Oct. 31, 2022	$ 28,200,000	$ 309,000	$ 247,123,000	$ (218,385,000)	$ 29,047,000	$ (847,000)
Balance, shares at Oct. 31, 2022		30,913,902
Stock option compensation to employees and directors	957,000		957,000		957,000
Stock options issued to consultants	81,000		81,000		81,000
Common stock issued to consultants	25,000		25,000		25,000
Common stock issued to consultants, shares		7,364
Common stock issued upon exercise of stock options	3,000		3,000		3,000
Net loss	(2,354,000)			(2,322,000)	(2,322,000)	(32,000)
Balance at Jan. 31, 2023	26,912,000	$ 309,000	248,189,000	(220,707,000)	27,791,000	(879,000)
Balance, shares at Jan. 31, 2023		30,922,830
Common stock issued upon exercise of stock options, shares		1,564
Balance at Oct. 31, 2023	23,371,000	$ 311,000	252,222,000	(228,196,000)	24,337,000	(966,000)
Balance, shares at Oct. 31, 2023		31,145,219
Stock option compensation to employees and directors	1,108,000		1,108,000		1,108,000
Stock options issued to consultants	56,000		56,000		56,000
Common stock issued to consultants	96,000	$ 1,000	95,000		96,000
Common stock issued to consultants, shares		29,336
Common stock issued in an at-the-market offering, net of offering expenses of $68	$ 2,196,000	$ 6,000	2,190,000		2,196,000
Common stock issued in an at- the market offering, net of offering expenses of $68	555,820	555,820
Common stock issued upon exercise of stock options	$ 67,000		67,000		67,000
Common stock issued pursuant to employee stock purchase plan, shares		24,000
Net loss	(3,290,000)			(3,255,000)	(3,255,000)	(35,000)
Balance at Jan. 31, 2024	$ 23,604,000	$ 318,000	$ 255,738,000	$ (231,451,000)	$ 24,605,000	$ (1,001,000)
Balance, shares at Jan. 31, 2024		31,754,375

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Equity (Unaudited) (Parenthetical) $ in Thousands	3 Months Ended
	Jan. 31, 2024 USD ($)
Statement of Cash Flows [Abstract]
Offering costs	$ 68

Condensed Consolidated Statem_5

Condensed Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Reconciliation of net loss to net cash used in operating activities:
Net loss	$ (3,290)	$ (2,354)
Stock option compensation to employees and directors	1,108	957
Stock options issued to consultants	56	81
Common stock issued to consultants	96	25
Amortization of operating lease right-to-use asset	13	11
Change in operating assets and liabilities:
Receivables	(121)	(100)
Prepaid expenses and other current assets	212	210
Accounts payable	158	(155)
Accrued expenses	(528)	(651)
Operating lease liability	(13)	(12)
Net cash used in operating activities	(2,309)	(1,988)
Cash flows from investing activities:
Disbursements to acquire short-term investments	(20,020)	(7,835)
Proceeds from maturities of short-term investments	20,149	7,250
Net cash provided by (used in) investing activities	129	(585)
Cash flows from financing activities:
Net proceeds from sale of common stock in an at-the-market offering	2,196
Proceeds from exercise of stock options	67	3
Net cash provided by financing activities	2,263	3
Net increase (decrease) in cash and cash equivalents	83	(2,570)
Cash and cash equivalents at beginning of period	915	12,360
Cash and cash equivalents at end of period	$ 998	$ 9,790

BUSINESS AND FUNDING

BUSINESS AND FUNDING	3 Months Ended
BUSINESS AND FUNDING	Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BUSINESS AND FUNDING	1. BUSINESS AND FUNDING Description of Business As used herein, “we,” “us,” “our,” the “Company” or “Anixa” means Anixa Biosciences, Inc. and its consolidated subsidiaries unless otherwise indicated. Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Our vaccine programs include (i) the development of a preventative vaccine against triple negative breast cancer (“TNBC”), the most lethal form of breast cancer, as well other forms of breast cancer and (ii) the development of a preventative vaccine against ovarian cancer. Our therapeutics programs include (i) the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (“CAR-T”) technology, initially focused on treating ovarian cancer, which is being developed at our subsidiary, Certainty Therapeutics, Inc. (“Certainty”), and (ii) until March 2023, the development of anti-viral drug candidates for the treatment of Covid-19. We hold an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Cleveland Clinic Foundation (“Cleveland Clinic”) relating to certain breast cancer vaccine technology developed at Cleveland Clinic. The license agreement requires us to make certain cash payments to Cleveland Clinic upon achievement of specific development milestones. Utilizing this technology, we are working in collaboration with Cleveland Clinic to develop a method to vaccinate women against contracting breast cancer, focused initially on TNBC. The focus of this vaccine is a specific protein, α-lactalbumin, that is only expressed during lactation in a healthy woman’s mammary tissue. This protein disappears when the woman is no longer lactating, but reappears in many forms of breast cancer, especially TNBC. Studies have shown that vaccinating against this protein prevents breast cancer in mice. In October 2021, following the U.S. Food and Drug Administration’s (“FDA”) authorization to proceed, we commenced dosing patients in a Phase 1 clinical trial of our breast cancer vaccine. This study, which is being funded by a U.S. Department of Defense grant to Cleveland Clinic, is a multiple-ascending dose Phase 1 trial to determine the maximum tolerated dose (“MTD”) of the vaccine in patients with early-stage, triple-negative breast cancer as well as monitor immune response. The study is being conducted at Cleveland Clinic. The first segment of the study, Phase 1a, will consist of 18 to 24 patients who have completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence. Studies show that 42% of TNBC patients will have a recurrence of their cancer, with most of the recurrences occurring in the first two to three years after standard of care treatment. During the course of the Phase 1a study, participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response. In January 2023, the number of participants in each dose cohort was expanded, and as of August 2023, we had completed vaccinating all patients in these expanded cohorts. In December 2023, we presented the immunological data collected to date at the San Antonio Breast Cancer Symposium. The data presented show that in the vaccinated women who had been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. We have begun vaccinating participants in up to three additional dose cohorts at dose levels higher than the currently determined MTD and lower than the highest dose where we observed dose limiting side effects. Further, we have commenced vaccination of participants in the second segment of the trial, Phase 1b, that includes participants who have never had cancer, but carry certain mutations in genes such as BRCA1, BRCA2 or PALB2, that indicate a greater risk of developing TNBC in the future, and have elected to have a prophylactic mastectomy. Finally, we have commenced vaccination of participants in the third segment of the trial, Phase 1c, that includes post-operative TNBC patients that have residual disease following treatment and are currently undergoing treatment with pembrolizumab (Keytruda®). In November 2020, we executed a license agreement with Cleveland Clinic pursuant to which the Company was granted an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by Cleveland Clinic relating to certain ovarian cancer vaccine technology. The license agreement requires us to make certain cash payments to Cleveland Clinic upon achievement of specific development milestones. This technology pertains to among other things, the use of vaccines for the treatment or prevention of ovarian cancers which express the anti-Mullerian hormone receptor 2 protein containing an extracellular domain (“AMHR2-ED”). In healthy tissue, this protein regulates growth and development of egg-containing follicles in the ovary. While expression of AMHR2-ED naturally and markedly declines during menopause, this protein is expressed at high levels in the ovaries of postmenopausal women with ovarian cancer. Researchers at Cleveland Clinic believe that a vaccine targeting AMHR2-ED could prevent the occurrence of ovarian cancer. In May 2021, Cleveland Clinic was granted acceptance for our ovarian cancer vaccine technology into the National Cancer Institute’s (“NCI”) PREVENT program. The NCI is a part of the National Institutes of Health (“NIH”). The PREVENT program is a peer-reviewed agent development program designed to support pre-clinical development of innovative interventions and biomarkers for cancer prevention and interception towards clinical trials. The scientific and financial resources of the PREVENT program are being used for our ovarian cancer vaccine technology to perform virtually all pre-clinical research and development, manufacturing and Investigational New Drug (“IND”) application enabling studies. This work is being performed at NCI facilities, by NCI scientific staff and with NCI financial resources and will require no material financial expenditures by the Company, nor the payment of any future consideration by the Company to NCI. Our subsidiary, Certainty, is developing immuno-therapy drugs against cancer. Certainty holds an exclusive worldwide, royalty-bearing license to use certain intellectual property owned or controlled by The Wistar Institute (“Wistar”), the nation’s first independent biomedical research institute and a leading NCI designated cancer research center, relating to Wistar’s chimeric endocrine receptor targeted therapy technology. We have initially focused on the development of a treatment for ovarian cancer, but we also may pursue applications of the technology for the development of treatments for additional solid tumors. The license agreement requires Certainty to make certain cash and equity payments to Wistar upon achievement of specific development milestones. With respect to Certainty’s equity obligations to Wistar, Certainty issued to Wistar shares of its common stock equal to five percent ( 5 4.6 Certainty, in collaboration with the H. Lee Moffitt Cancer Center and Research Institute, Inc. (“Moffitt”), has begun human clinical testing of the CAR-T technology licensed by Certainty from Wistar aimed initially at treating ovarian cancer. After receiving authorization from the FDA, we commenced enrollment of patients in a Phase 1 clinical trial and treated the first patient in August 2022. Further, in May 2023 and August 2023, we treated the second and third patients in the trial, respectively, at the same dose level as the first patient, and the treatment was well-tolerated by the patients. In February 2024, we treated the first patient in the second dose cohort, where the patient was administered a three-times higher dose of cells than the patients in the first cohort. The treatment appears to have been well-tolerated by the patient. This study is a dose-escalation trial with two arms based on route of delivery—intraperitoneal or intravenous—to determine the maximum tolerated dose in patients with recurrent epithelial ovarian cancer and to assess persistence, expansion and efficacy of the modified T cells. The study is being conducted at Moffitt and will consist of 24 to 48 patients who have received at least two prior lines of chemotherapy. The study is estimated to be completed in two to four years depending on multiple factors including when maximum tolerated dose is reached, the rate of patient enrollment, and how long we maintain the two different delivery methods. Over the next several quarters, we expect the development of our vaccines and therapeutics to be the primary focus of the Company. As part of our legacy operations, the Company remains engaged in limited patent licensing activities of its various patent portfolios. We do not expect these activities to be a significant part of the Company’s ongoing operations nor do we expect these activities to require material financial resources or attention of senior management. Over the past several years, our revenue was derived from technology licensing and the sale of patented technologies, including revenue from the settlement of litigation. We have not generated any revenue to date from our vaccine or therapeutics programs. In addition, while we pursue our vaccine and therapeutics programs, we may also make investments in and form new companies to develop additional emerging technologies. We do not expect to begin generating revenue with respect to any of our current vaccine or therapy programs in the near term. We hope to achieve a profitable outcome by eventually licensing our technologies to large pharmaceutical companies that have the resources and infrastructure in place to manufacture, market and sell our technologies as vaccines or therapeutics. The eventual licensing of any of our technologies may take several years, if it is to occur at all, and may depend on positive results from human clinical trials. Funding and Management’s Plans Based on currently available information as of March 12, 2024, we believe that our existing cash, cash equivalents, short-term investments and expected cash flows will be sufficient to fund our activities for at least the next twelve months. We have implemented a business model that conserves funds by collaborating with third parties to develop our technologies. However, our projections of future cash needs and cash flows may differ from actual results. If current cash on hand, cash equivalents, short-term investments and cash that may be generated from our business operations are insufficient to continue to operate our business, or if we elect to invest in or acquire a company or companies or new technology or technologies that are synergistic with or complementary to our technologies, we may be required to obtain more working capital. During the three months ended January 31, 2024, we raised approximately $ 2,196,000 555,820 100 98

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Jan. 31, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The accompanying October 31, 2023 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2024, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2024 are not necessarily indicative of the results to be expected for the year. Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2024 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2023 $ (966 ) Net loss attributable to noncontrolling interest (35 ) Balance, January 31, 2024 $ (1,001 ) Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these arrangements are satisfied and 100 Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations. Research and Development Expenses Research and development expenses consist primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing our therapeutics and vaccines. We recognize research and development expenses as incurred. Advance payments for future research and development activities are deferred and expensed as the services are performed. We recognize our preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, clinical research organizations (“CROs”), clinical manufacturing organizations (“CMOs”), and other parties that conduct and manage various stages of research and development activities on our behalf. Fees for such services are recognized based on management’s estimates after considering the activities and tasks completed by each service provider in a given period, the time period over which services are expected to be performed, and the level of effort expended in each reporting period. Investment Policy The Company’s investment policy is to acquire debt securities with fixed maturities and contractual cash flows that the Company has the positive intent and ability to hold to maturity. These securities are recorded at amortized cost, net of any applicable discount which is amortized to interest income, and are accounted for as held-to-maturity securities.

STOCK BASED COMPENSATION

STOCK BASED COMPENSATION	3 Months Ended
STOCK BASED COMPENSATION	Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK BASED COMPENSATION	3. STOCK BASED COMPENSATION The Company maintains stock equity incentive plans under which the Company may grant incentive stock options, non-qualified stock options, stock appreciation rights, stock awards, performance awards, or stock units to employees, directors and consultants. Stock Option Compensation Expense We account for stock options granted to employees, directors and consultants using the accounting guidance in ASC 718, Stock Compensation (“ASC 718”). We estimate the fair value of service-based stock options on the date of grant, using the Black-Scholes pricing model, and recognize compensation expense over the requisite service period of the grant. We recorded stock-based compensation expense related to service-based stock options granted to employees and directors of approximately $ 1,108,000 957,000 The compensation cost for service-based stock options granted to consultants is measured at the grant date, based on the fair value of the award using the Black-Scholes pricing model, and is expensed on a straight-line basis over the requisite service period (the vesting period of the stock option) which is one to three years. We recorded stock-based consulting expense related to stock options granted to consultants of approximately $ 56,000 81,000 Stock Option Plans During the three months ended January 31, 2024, we had two stock option plans: the Anixa Biosciences, Inc. 2010 Share Incentive Plan (the “2010 Share Plan”) and the Anixa Biosciences, Inc. 2018 Share Incentive Plan (the “2018 Share Plan”), which were adopted by our Board of Directors on July 14, 2010 and January 25, 2018, respectively. The 2018 Share Plan was approved by our shareholders on March 29, 2018. Stock Option Activity During the three months ended January 31, 2024 and 2023, we granted options to purchase 1,335,000 1,505,000 4.19 4.81 24,000 1,261 67,000 3,000 1,111 808 no 2010 Share Plan The 2010 Share Plan provided for the grant of nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. In accordance with the provisions of the 2010 Share Plan, the plan terminated with respect to the ability to grant future awards on July 14, 2020. Information regarding the 2010 Share Plan for the three months ended January 31, 2024 is as follows: SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2023 1,189,000 $ 2.94 Exercised (13,000 ) 2.92 Options outstanding and exercisable at January 31, 2024 1,176,000 $ 2.94 $ 2,012 The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Weighted Average Weighted $ 0.67 2.27 366,000 3.3 $ 1.27 $ 2.58 3.13 301,000 2.0 $ 2.91 $ 3.46 5.30 509,000 4.3 $ 4.17 2018 Share Plan The 2018 Share Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, performance awards and stock units to employees, directors and consultants. As of January 31, 2024, the 2018 Share Plan had 883,906 SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2023 10,241,000 $ 3.67 Granted 1,335,000 $ 4.39 Exercised (11,000 ) $ 2.68 Forfeited/Expired (243,906 ) 4.31 Options outstanding at January 31, 2024 11,321,094 $ 3.74 $ 9,236 Options exercisable at January 31, 2024 7,085,397 $ 3.51 $ 7,083 The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Number Weighted Weighted Number Weighted Weighted $ 2.09 3.87 5,458,879 6.2 $ 3.24 4,976,100 5.9 $ 3.28 $ 3.96 5.30 5,862,215 8.2 $ 4.20 2,109,297 7.2 $ 4.04 Employee Stock Purchase Plan The Company maintains the Anixa Biosciences, Inc. Employee Stock Purchase Plan (the “ESPP”) which permits eligible employees to purchase shares at not less than 85 no Warrants As of January 31, 2024, we had warrants outstanding to purchase 300,000 6.56 March 22, 2026 Information regarding the Company’s warrants for the three months ended January 31, 2024 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Aggregate Warrants Outstanding at October 31, 2023 300,000 $ 6.56 Warrants Outstanding and Exercisable at January 31, 2024 300,000 $ 6.56 $ 0 The following table summarizes information about the Company’s outstanding and exercisable warrants as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 6.56 300,000 2.1 $ 6.56

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
FAIR VALUE MEASUREMENTS	Jan. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	4. FAIR VALUE MEASUREMENTS US GAAP defines fair value and establishes a framework for measuring fair value. We have categorized our financial assets and liabilities, based on the priority of the inputs to the valuation technique, into a three-level fair value hierarchy as set forth below. If the inputs used to measure the financial instruments fall within different levels of the hierarchy, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. Financial assets and liabilities recorded in the accompanying condensed consolidated balance sheets are categorized based on the inputs to the valuation techniques as follows: Level 1 – Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which we have the ability to access at the measurement date. Level 2 – Financial instruments whose values are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets. Level 3 – Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management’s own assumptions about the assumptions a market participant would use in pricing the instrument. The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2024 (in thousands): SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 855 $ - $ - $ 855 U.S. treasury bills: Short-term investments - 22,800 - 22,800 Total financial assets $ 855 $ 22,800 $ - $ 23,655 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2023 (in thousands): Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 778 $ - $ - $ 778 Money market funds Cash equivalents $ 778 $ - $ - $ 778 Certificates of deposit: Short term investments - 720 - 720 Certificates of deposit Short term investments - 720 - 720 U.S. treasury bills: Short-term investments - 22,209 - 22,209 U.S. treasury bills Short-term investments - 22,209 - 22,209 Total financial assets $ 778 $ 22,929 $ - $ 23,707 Our non-financial assets that are measured on a non-recurring basis are property and equipment and other assets which are measured using fair value techniques whenever events or changes in circumstances indicate a condition of impairment exists. The estimated fair value of prepaid expenses and other current assets, accounts payable and accrued expenses approximates their individual carrying amounts due to the short-term nature of these measurements. Cash equivalents are stated at carrying value which approximates fair value.

ACCRUED EXPENSES

ACCRUED EXPENSES	3 Months Ended
ACCRUED EXPENSES	Jan. 31, 2024
Payables and Accruals [Abstract]
ACCRUED EXPENSES	5. ACCRUED EXPENSES Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES January 31, October 31, 2024 2023 (in thousands) Payroll and related expenses $ 552 $ 1,114 Accrued royalty and contingent legal fees 626 626 Accrued other 64 30 Accrued expenses $ 1,242 $ 1,770

NET LOSS PER SHARE OF COMMON ST

NET LOSS PER SHARE OF COMMON STOCK	3 Months Ended
NET LOSS PER SHARE OF COMMON STOCK	Jan. 31, 2024
Net loss per common share attributable to common shareholders:
NET LOSS PER SHARE OF COMMON STOCK	6. NET LOSS PER SHARE OF COMMON STOCK Basic net loss per common share (“Basic EPS”) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (“Diluted EPS”) is computed by dividing net loss by the weighted average number of common shares and dilutive common share equivalents and convertible securities then outstanding. Diluted EPS for all periods presented is the same as Basic EPS, as the inclusion of the effect of common share equivalents then outstanding would be anti-dilutive. For this reason, excluded from the calculation of Diluted EPS for the three months ended January 31, 2024 and 2023, were stock options to purchase 12,497,094 11,821,500 300,000 300,000

EFFECT OF RECENTLY ADOPTED AND

EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	3 Months Ended
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	Jan. 31, 2024
Effect Of Recently Adopted And Issued Pronouncements
EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS	7. EFFECT OF RECENTLY ADOPTED AND ISSUED PRONOUNCEMENTS In October 2021, the FASB issued Accounting Standards Update 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, to require that an acquirer recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606, Revenue from Contracts with Customers. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. The amendments in this update should be applied prospectively and are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial statements and related disclosures.

INCOME TAXES

INCOME TAXES	3 Months Ended
INCOME TAXES	Jan. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	8. INCOME TAXES We recognize deferred tax assets and liabilities for the estimated future tax effects of events that have been recognized in our financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. A valuation allowance is established, when necessary, to reduce deferred tax assets to the amount expected to be realized. We have provided a full valuation allowance against our deferred tax asset due to our historical pre-tax losses and the uncertainty regarding the realizability of these deferred tax assets. We have substantial net operating loss carryforwards for Federal and California income tax returns. These net operating loss carryforwards could be subject to limitations under Internal Revenue Code section 382, the effects of which have not been determined by the Company. We have no

LEASES

LEASES	3 Months Ended
LEASES	Jan. 31, 2024
Leases [Abstract]
LEASES	9. LEASES We lease approximately 2,000 September 30, 2024 an option to extend the lease an additional two years 5,000 3% 260,000 10% 17,000 17,000 For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments. The remaining 32 As of January 31, 2024, the annual minimum future lease payments of our operating lease liabilities were as follows (in thousands): SCHEDULE OF MINIMUM LEASE PAYMENTS For years Ended October 31, Operating 2024 $ 51 2025 70 2026 65 Total future minimum lease payments, undiscounted 186 Less: Imputed interest (24 ) Present value of future minimum lease payments $ 162

COMMITMENTS AND CONTINGENCES

COMMITMENTS AND CONTINGENCES	3 Months Ended
COMMITMENTS AND CONTINGENCES	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCES	10. COMMITMENTS AND CONTINGENCES Litigation Matters Other than lawsuits related to the enforcement of our patent rights, we are not a party to any material pending legal proceedings, nor are we aware of any pending litigation or legal proceeding against us that would have a material adverse effect upon our results of operations or financial condition. License Commitments As of January 31, 2024, our commitments under certain technology license agreements related to our therapeutic and vaccine development programs for the remainder of fiscal year 2024, were approximately $ 14,000 Research & Development Agreements We have entered into certain research and development agreements with various third-party vendors related to the manufacturing and stability testing of the materials necessary for the development of our breast cancer vaccine and our CAR-T therapeutic. As of January 31, 2024, future payments the Company may make under these agreements, dependent upon, among other things, development of analytical methods, formulation feasibility studies, stability testing, and results of manufacturing processes, may be approximately $ 3.6 five-year

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
SEGMENT INFORMATION	Jan. 31, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	11. SEGMENT INFORMATION We follow the accounting guidance of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the three months ended January 31, 2024 and 2023 and as of January 31, 2024 and October 31, 2023 (in thousands): SCHEDULE OF SEGMENT INFORMATION 2024 2023 For the Three Months Ended 2024 2023 Net loss: CAR-T Therapeutics $ (1,525 ) $ (911 ) Cancer Vaccines (1,756 ) (958 ) Anti-Viral Therapeutics - (482 ) Other (9 ) (3 ) Total $ (3,290 ) $ (2,354 ) Net loss $ (3,290 ) $ (2,354 ) Total operating costs and expenses $ 3,609 $ 2,556 Less non-cash share-based compensation (1,260 ) (1,063 ) Operating costs and expenses excluding non-cash share-based compensation $ 2,349 $ 1,493 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 1,128 $ 598 Cancer Vaccines 1,213 588 Anti-Viral Therapeutics - 305 Other 8 2 Total $ 2,349 $ 1,493 Operating costs and expenses excluding non-cash share based compensation $ 2,349 $ 1,493 January 31, October 31, Total assets: CAR-T Therapeutics $ 12,124 $ 7,523 Cancer Vaccines 13,162 17,215 Anti-Viral Therapeutics - 700 Other 86 84 Total $ 25,372 $ 25,522 Total assets $ 25,372 $ 25,522 Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Policies)	Jan. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and disclosures required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures included in our Annual Report on Form 10-K for the fiscal year ended October 31, 2023. The accompanying October 31, 2023 condensed consolidated balance sheet data was derived from the audited financial statements but does not include all disclosures required by US GAAP. The condensed consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of January 31, 2024, and results of operations and cash flows for the interim periods represented. The results of operations for the three months ended January 31, 2024 are not necessarily indicative of the results to be expected for the year.
Noncontrolling Interest	Noncontrolling Interest Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2024 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2023 $ (966 ) Net loss attributable to noncontrolling interest (35 ) Balance, January 31, 2024 $ (1,001 )
Revenue Recognition	Revenue Recognition Our revenue has been derived solely from technology licensing and the sale of patented technologies. Revenue is recognized upon transfer of control of intellectual property rights and satisfaction of other contractual performance obligations to licensees in an amount that reflects the consideration we expect to receive. Our revenue recognition policy requires us to make certain judgments and estimates in connection with the accounting for revenue. Such areas may include determining the existence of a contract and identifying each party’s rights and obligations to transfer goods and services, identifying the performance obligations in the contract, determining the transaction price and allocating the transaction price to separate performance obligations, estimating the timing of satisfaction of performance obligations, determining whether a promise to grant a license is distinct from other promised goods or services and evaluating whether a license transfers to a customer at a point in time or over time. Our revenue arrangements provide for the payment, within 30 days of execution of the agreement, of contractually determined, one-time, paid-up license fees in settlement of litigation and in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. These arrangements typically include some combination of the following: (i) the grant of a non-exclusive, retroactive and future license to manufacture and/or sell products covered by patented technologies owned or controlled by the Company, (ii) a covenant-not-to-sue, (iii) the release of the licensee from certain claims, and (iv) the dismissal of any pending litigation. In such instances, the intellectual property rights granted have been perpetual in nature, extending until the expiration of the related patents. Pursuant to the terms of these agreements, we have no further obligations with respect to the granted intellectual property rights, including no obligation to maintain or upgrade the technology, or provide future support or services. Licensees obtained control of the intellectual property rights they have acquired upon execution of the agreement. Accordingly, the performance obligations from these arrangements are satisfied and 100
Cost of Revenues	Cost of Revenues Cost of revenues include the costs and expenses incurred in connection with our patent licensing and enforcement activities, including inventor royalties paid to original patent owners, contingent legal fees paid to external counsel, other patent-related legal expenses paid to external counsel and licensing and enforcement related research, consulting and other expenses paid to third-parties. These costs are included under the caption “Operating costs and expenses” in the accompanying condensed consolidated statements of operations.
Research and Development Expenses	Research and Development Expenses Research and development expenses consist primarily of employee compensation, payments to third parties for research and development activities and other direct costs associated with developing our therapeutics and vaccines. We recognize research and development expenses as incurred. Advance payments for future research and development activities are deferred and expensed as the services are performed. We recognize our preclinical studies and clinical trial expenses based on the services performed pursuant to contracts with research institutions, clinical research organizations (“CROs”), clinical manufacturing organizations (“CMOs”), and other parties that conduct and manage various stages of research and development activities on our behalf. Fees for such services are recognized based on management’s estimates after considering the activities and tasks completed by each service provider in a given period, the time period over which services are expected to be performed, and the level of effort expended in each reporting period.
Investment Policy	Investment Policy The Company’s investment policy is to acquire debt securities with fixed maturities and contractual cash flows that the Company has the positive intent and ability to hold to maturity. These securities are recorded at amortized cost, net of any applicable discount which is amortized to interest income, and are accounted for as held-to-maturity securities.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Tables)	Jan. 31, 2024
Accounting Policies [Abstract]
SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST	Noncontrolling interest represents Wistar’s equity ownership in Certainty and is presented as a component of equity. The following table sets forth the changes in noncontrolling interest for the three months ended January 31, 2024 (in thousands): SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST Balance, October 31, 2023 $ (966 ) Net loss attributable to noncontrolling interest (35 ) Balance, January 31, 2024 $ (1,001 )

STOCK BASED COMPENSATION (Table

STOCK BASED COMPENSATION (Tables)	3 Months Ended
STOCK BASED COMPENSATION (Tables)	Jan. 31, 2024
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about the Company’s outstanding and exercisable warrants as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Exercise Prices Number Outstanding and Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 6.56 300,000 2.1 $ 6.56
SCHEDULE OF WARRANTS ACTIVITY	Information regarding the Company’s warrants for the three months ended January 31, 2024 is as follows: SCHEDULE OF WARRANTS ACTIVITY Shares Weighted Aggregate Warrants Outstanding at October 31, 2023 300,000 $ 6.56 Warrants Outstanding and Exercisable at January 31, 2024 300,000 $ 6.56 $ 0
2010 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Options outstanding at October 31, 2023 1,189,000 $ 2.94 Exercised (13,000 ) 2.92 Options outstanding and exercisable at January 31, 2024 1,176,000 $ 2.94 $ 2,012
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2010 Share Plan as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Range of Number Weighted Average Weighted $ 0.67 2.27 366,000 3.3 $ 1.27 $ 2.58 3.13 301,000 2.0 $ 2.91 $ 3.46 5.30 509,000 4.3 $ 4.17
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
SCHEDULE OF OPTION ACTIVITY	SCHEDULE OF OPTION ACTIVITY Shares Weighted Aggregate Intrinsic Value Options outstanding at October 31, 2023 10,241,000 $ 3.67 Granted 1,335,000 $ 4.39 Exercised (11,000 ) $ 2.68 Forfeited/Expired (243,906 ) 4.31 Options outstanding at January 31, 2024 11,321,094 $ 3.74 $ 9,236 Options exercisable at January 31, 2024 7,085,397 $ 3.51 $ 7,083
SCHEDULE OF OUTSTANDING AND EXERCISABLE	The following table summarizes information about stock options outstanding and exercisable under the 2018 Share Plan as of January 31, 2024: SCHEDULE OF OUTSTANDING AND EXERCISABLE Options Outstanding Options Exercisable Range of Number Weighted Weighted Number Weighted Weighted $ 2.09 3.87 5,458,879 6.2 $ 3.24 4,976,100 5.9 $ 3.28 $ 3.96 5.30 5,862,215 8.2 $ 4.20 2,109,297 7.2 $ 4.04

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
FAIR VALUE MEASUREMENTS (Tables)	Jan. 31, 2024
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS	The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of January 31, 2024 (in thousands): SCHEDULE OF FAIR VALUE MEASUREMENTS Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 855 $ - $ - $ 855 U.S. treasury bills: Short-term investments - 22,800 - 22,800 Total financial assets $ 855 $ 22,800 $ - $ 23,655 The following table presents the hierarchy for our financial assets measured at fair value on a recurring basis as of October 31, 2023 (in thousands): Level 1 Level 2 Level 3 Total Money market funds: Cash equivalents $ 778 $ - $ - $ 778 Money market funds Cash equivalents $ 778 $ - $ - $ 778 Certificates of deposit: Short term investments - 720 - 720 Certificates of deposit Short term investments - 720 - 720 U.S. treasury bills: Short-term investments - 22,209 - 22,209 U.S. treasury bills Short-term investments - 22,209 - 22,209 Total financial assets $ 778 $ 22,929 $ - $ 23,707

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	3 Months Ended
ACCRUED EXPENSES (Tables)	Jan. 31, 2024
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES	Accrued expenses consist of the following as of: SCHEDULE OF ACCRUED EXPENSES January 31, October 31, 2024 2023 (in thousands) Payroll and related expenses $ 552 $ 1,114 Accrued royalty and contingent legal fees 626 626 Accrued other 64 30 Accrued expenses $ 1,242 $ 1,770

LEASES (Tables)

LEASES (Tables)	3 Months Ended
LEASES (Tables)	Jan. 31, 2024
Leases [Abstract]
SCHEDULE OF MINIMUM LEASE PAYMENTS	As of January 31, 2024, the annual minimum future lease payments of our operating lease liabilities were as follows (in thousands): SCHEDULE OF MINIMUM LEASE PAYMENTS For years Ended October 31, Operating 2024 $ 51 2025 70 2026 65 Total future minimum lease payments, undiscounted 186 Less: Imputed interest (24 ) Present value of future minimum lease payments $ 162

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
SEGMENT INFORMATION (Tables)	Jan. 31, 2024
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT INFORMATION	SCHEDULE OF SEGMENT INFORMATION 2024 2023 For the Three Months Ended 2024 2023 Net loss: CAR-T Therapeutics $ (1,525 ) $ (911 ) Cancer Vaccines (1,756 ) (958 ) Anti-Viral Therapeutics - (482 ) Other (9 ) (3 ) Total $ (3,290 ) $ (2,354 ) Net loss $ (3,290 ) $ (2,354 ) Total operating costs and expenses $ 3,609 $ 2,556 Less non-cash share-based compensation (1,260 ) (1,063 ) Operating costs and expenses excluding non-cash share-based compensation $ 2,349 $ 1,493 Operating costs and expenses excluding non-cash CAR-T Therapeutics $ 1,128 $ 598 Cancer Vaccines 1,213 588 Anti-Viral Therapeutics - 305 Other 8 2 Total $ 2,349 $ 1,493 Operating costs and expenses excluding non-cash share based compensation $ 2,349 $ 1,493 January 31, October 31, Total assets: CAR-T Therapeutics $ 12,124 $ 7,523 Cancer Vaccines 13,162 17,215 Anti-Viral Therapeutics - 700 Other 86 84 Total $ 25,372 $ 25,522 Total assets $ 25,372 $ 25,522

BUSINESS AND FUNDING (Details N

BUSINESS AND FUNDING (Details Narrative) - USD ($)	3 Months Ended
BUSINESS AND FUNDING (Details Narrative) - USD ($)	Jan. 31, 2024	Jan. 31, 2023
Capital raised by issuance of shares	$ 2,196,000
Issuance of shares	555,820
Proceeds from Issuance of Common Stock	$ 2,196,000
Maximum [Member]
Proceeds from Issuance of Common Stock	100,000,000
Additional proceeds from sale of stock	$ 98,000,000
The Wistar Institute [Member]
Percenatge of shares issued for common stock	5%
Equity Method Investment, Ownership Percentage	4.60%

SCHEDULE OF CHANGES IN NONCONTR

SCHEDULE OF CHANGES IN NONCONTROLLING INTEREST (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Accounting Policies [Abstract]
Beginning balance	$ (966)
Net loss attributable to noncontrolling interest	(35)	$ (32)
Ending balance	$ (1,001)

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	3 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Jan. 31, 2024
Accounting Policies [Abstract]
Revenue recognition percentage	100%

SCHEDULE OF OPTION ACTIVITY (De

SCHEDULE OF OPTION ACTIVITY (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Jan. 31, 2024 USD ($) $ / shares shares
2010 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, options outstanding, beginning balance \| shares	1,189,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance \| $ / shares	$ 2.94
Shares, options, exercised \| shares	(13,000)
Weighted average exercise price per share, exercised \| $ / shares	$ 2.92
Shares, options outstanding, ending balance \| shares	1,176,000
Weighted Average Exercise Price Per Share, Outstanding ending balance \| $ / shares	$ 2.94
Aggregate intrinsic value, outstanding and exercisable \| $	$ 2,012
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, options outstanding, beginning balance \| shares	10,241,000
Weighted Average Exercise Price Per Share, Outstanding Beginning balance \| $ / shares	$ 3.67
Shares, options, exercised \| shares	(11,000)
Weighted average exercise price per share, exercised \| $ / shares	$ 2.68
Shares, options outstanding, ending balance \| shares	11,321,094
Weighted Average Exercise Price Per Share, Outstanding ending balance \| $ / shares	$ 3.74
Shares, options, granted \| shares	1,335,000
Weighted Average Exercise Price Per Share, Granted \| $ / shares	$ 4.39
Shares, options, forfeited/expired \| shares	(243,906)
Weighted average exercise price per share, forfeited/expired \| $ / shares	$ 4.31
Aggregate Intrinsic Value, Outstanding Ending balance \| $	$ 9,236
Shares, Options outstanding, Exercisable \| shares	7,085,397
Weighted Average Exercise Price Per Share, Exercisable \| $ / shares	$ 3.51
Aggregate Intrinsic Value, Exercisable \| $	$ 7,083

SCHEDULE OF OUTSTANDING AND EXE

SCHEDULE OF OUTSTANDING AND EXERCISABLE (Details) - $ / shares	3 Months Ended
	Jan. 31, 2024	Oct. 31, 2023
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	300,000
Weighted average remaining contractual life	2 years 1 month 6 days
Weighted average exercise price	$ 6.56
Range of exercise prices	$ 6.56
2010 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	1,176,000	1,189,000
Weighted average exercise price	$ 2.94	$ 2.94
2010 Plan [Member] \| Range One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices	0.67
Range of Exercise Prices	$ 2.27
Number outstanding and exercisable	366,000
Weighted average remaining contractual life	3 years 3 months 18 days
Weighted average exercise price	$ 1.27
2010 Plan [Member] \| Range Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices	2.58
Range of Exercise Prices	$ 3.13
Number outstanding and exercisable	301,000
Weighted average remaining contractual life	2 years
Weighted average exercise price	$ 2.91
2010 Plan [Member] \| Range Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices	3.46
Range of Exercise Prices	$ 5.30
Number outstanding and exercisable	509,000
Weighted average remaining contractual life	4 years 3 months 18 days
Weighted average exercise price	$ 4.17
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number outstanding and exercisable	11,321,094	10,241,000
Weighted average exercise price	$ 3.74	$ 3.67
Number of Options Outstanding and Exercisable	7,085,397
Weighted average exercise price, options exercisable	$ 3.51
2018 Share Plan [Member] \| Range One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices	2.09
Range of Exercise Prices	$ 3.87
Number outstanding and exercisable	5,458,879
Weighted average remaining contractual life	6 years 2 months 12 days
Weighted average exercise price	$ 3.24
Number of Options Outstanding and Exercisable	4,976,100
Weighted average remaining contractual life (in years), options exercisable	5 years 10 months 24 days
Weighted average exercise price, options exercisable	$ 3.28
2018 Share Plan [Member] \| Range Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Range of Exercise Prices	3.96
Range of Exercise Prices	$ 5.30
Number outstanding and exercisable	5,862,215
Weighted average remaining contractual life	8 years 2 months 12 days
Weighted average exercise price	$ 4.20
Number of Options Outstanding and Exercisable	2,109,297
Weighted average remaining contractual life (in years), options exercisable	7 years 2 months 12 days
Weighted average exercise price, options exercisable	$ 4.04

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] $ / shares in Units, $ in Thousands	Jan. 31, 2024 USD ($) $ / shares shares
Warrants outstanding, ending balance \| shares	300,000
Weighted average exercise price per share warrants outstanding, ending balance \| $ / shares	$ 6.56
Warrants outstanding and exercisable, ending balance \| shares	300,000
Weighted average exercise price per share warrants outstanding and exercisable, ending balance \| $ / shares	$ 6.56
Aggregate intrinsic value, Warrants outstanding and exercisable, ending balance \| $	$ 0

STOCK BASED COMPENSATION (Detai

STOCK BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
STOCK BASED COMPENSATION (Details Narrative) - USD ($)	Jan. 31, 2024	Jan. 31, 2023	Oct. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option exercised	$ 67,000	$ 3,000
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option to purchase common stock	300,000
Warrants outstanding	300,000
Warrant per share	$ 6.56
Expire date	Mar. 22, 2026
Stock Option Activity [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option to purchase common stock	24,000	1,261
Stock option exercised	$ 67,000	$ 3,000
Option to purchase common stock	1,111
Option to purchase common stock withheld	808
Cashless basis	0
2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted	1,335,000
Option to purchase common stock	11,321,094		10,241,000
Cashless basis	11,000
Shares for grant	883,906
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase percent			85%
Shares purchased	0
Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation	$ 1,108,000	957,000
Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted	$ 56,000	$ 81,000
Employees and Consultants [Member] \| 2018 Share Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares options, granted	1,335,000	1,505,000
Employees and Consultants [Member] \| 2018 Share Plan [Member] \| Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share exercise price	$ 4.19
Employees and Consultants [Member] \| 2018 Share Plan [Member] \| Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share exercise price	$ 4.81

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	$ 23,655	$ 23,707
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds Cash equivalents	855	778
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments	22,800	720
US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments		22,209
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	855	778
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds Cash equivalents	855	778
Fair Value, Inputs, Level 1 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments
Fair Value, Inputs, Level 1 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets	22,800	22,929
Fair Value, Inputs, Level 2 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds Cash equivalents
Fair Value, Inputs, Level 2 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments	22,800	720
Fair Value, Inputs, Level 2 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments		22,209
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total financial assets
Fair Value, Inputs, Level 3 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds Cash equivalents
Fair Value, Inputs, Level 3 [Member] \| Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments
Fair Value, Inputs, Level 3 [Member] \| US Treasury Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
U.S. treasury bills Short-term investments

SCHEDULE OF ACCRUED EXPENSES (D

SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jan. 31, 2024	Oct. 31, 2023
Payables and Accruals [Abstract]
Payroll and related expenses	$ 552	$ 1,114
Accrued royalty and contingent legal fees	626	626
Accrued other	64	30
Accrued expenses	$ 1,242	$ 1,770

NET LOSS PER SHARE OF COMMON _2

NET LOSS PER SHARE OF COMMON STOCK (Details Narrative) - shares	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	12,497,094	11,821,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	300,000	300,000

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Jan. 31, 2024	Oct. 31, 2023
Income Tax Disclosure [Abstract]
Unrecognized income tax benefits, penalties	$ 0	$ 0

SCHEDULE OF MINIMUM LEASE PAYME

SCHEDULE OF MINIMUM LEASE PAYMENTS (Details) $ in Thousands	Jan. 31, 2024 USD ($)
Leases [Abstract]
2024	$ 51
2025	70
2026	65
Total future minimum lease payments, undiscounted	186
Less: Imputed interest	(24)
Present value of future minimum lease payments	$ 162

LEASES (Details Narrative)

LEASES (Details Narrative) - Almaden Expressway San Jose [Member]	3 Months Ended
	Jan. 31, 2024 USD ($) ft²	Jan. 31, 2023 USD ($)
Area of land \| ft²	2,000
Lease expiration date	Sep. 30, 2024
Lease extension	an option to extend the lease an additional two years
Base rent	$ 5,000
Rent percentage	3%
Right of use asset obtained in exchange for operating lease liability	$ 260,000
Operating lease weighted average discount rate percent	10%
Payments for rent	$ 17,000	$ 17,000
Lessee operating lease term of contract	32 months

COMMITMENTS AND CONTINGENCES (D

COMMITMENTS AND CONTINGENCES (Details Narrative)	3 Months Ended
COMMITMENTS AND CONTINGENCES (Details Narrative)	Jan. 31, 2024 USD ($)
Research And Development Agreements [Member]
Other Commitments [Line Items]
Payments to acquire research and development	$ 3,600,000
Future payments over period	5 years
Agreement with Wistar Clevel and Clinic [Member]
Other Commitments [Line Items]
Legal license agreement	$ 14,000

SCHEDULE OF SEGMENT INFORMATION

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Oct. 31, 2023
Segment Reporting Information [Line Items]
Net loss	$ (3,290)	$ (2,354)
Total operating costs and expenses	3,609	2,556
Less non-cash share-based compensation	(1,260)	(1,063)
Operating costs and expenses excluding non-cash share based compensation	2,349	1,493
Total assets	25,372		$ 25,522
Cart Therapeutics [Member]
Segment Reporting Information [Line Items]
Net loss	(1,525)	(911)
Operating costs and expenses excluding non-cash share based compensation	1,128	598
Total assets	12,124		7,523
Cancer Vaccines [Member]
Segment Reporting Information [Line Items]
Net loss	(1,756)	(958)
Operating costs and expenses excluding non-cash share based compensation	1,213	588
Total assets	13,162		17,215
Anti Viral Therapeutics [Member]
Segment Reporting Information [Line Items]
Net loss		(482)
Operating costs and expenses excluding non-cash share based compensation		305
Total assets			700
Other [Member]
Segment Reporting Information [Line Items]
Net loss	(9)	(3)
Operating costs and expenses excluding non-cash share based compensation	8	$ 2
Total assets	$ 86		$ 84